Crystal NAX
Cranbury, NJ, United Statescrystalnax.comFrom their website, Nov 2026
- GMP
Work here? Claim this listing
About
Crystal NAX is a CRDMO focused on RNA therapeutics, nucleic acid engineering, lipid nanoparticle delivery, analytical characterization, and early-phase manufacturing. It works with academia, biotech, and pharmaceutical partners across the United States, Europe, and China from its facilities in Cranbury, New Jersey, and other global operations.
Services
DNA Synthesis
Provides cell-free linear DNA (LDNA) and plasmid DNA (pDNA) preparation to support RNA synthesis, screening, and preclinical development.
RNA Synthesis
Delivers mRNA, self-amplifying RNA (saRNA), circular RNA (circRNA), and high-fidelity sgRNA synthesis for research and preclinical use.
LNP Formulation
Offers standard LNP synthesis, targeted LNP development, high-throughput formulation screening, and process development studies.
Analytical & Characterization Services
Provides routine testing, extended characterization, method development and validation, and stability studies for RNA and nanoparticle systems.
Early-Phase Manufacturing
Provides early-phase manufacturing using GMP-like processes and controls for advanced preclinical development.
- Turnaround
- 8 days to 3 weeks
- What to send
- DNA synthesis order ranges by gene length: 1–1500 bp, 1500–3000 bp, 3000–5000 bp, >5000 bp TBD
- RNA synthesis accepts coding sequence input for custom synthesis
- LNP formulation accepts payload modalities including mRNA, saRNA, circRNA, mRNA + sgRNA, siRNA, DNA, and multi-payload
- LDNA high-throughput option: minimum 10 sequences/order
Capabilities
- Assays and studies
- LNP
- mRNA
- In vivo
- Cell therapy
- Cell-free expression
- HPLC
21 more
- CRISPR
- Analytical development
- Routine testing
- Extended characterization
- Method development
- Method validation
- Stability studies
- Physicochemical assays
- Biophysical assays
- Functional assays
- Appearance
- pH
- Identity
- Content
- Extinction coefficient
- A260/A280
- Integrity
- CE
- Purity
- Capping efficiency
- Poly(A) distribution
- Scale and capacity
- LDNA high-throughput option: minimum 10 sequences/order
- LDNA deliverables: 1 ug lyophilized linear DNA
- RNA synthesis scale: 100 ug to 10 g
- LNP formulation: 0.5–20 mg (microfluidics), 0.1–1 mg (traditional T mix), 1 mg–1 g (TurbMix by NAX)
- tLNP formulation: 0.1–5 mg
- DNA preparation from micrograms to milligrams
8 more
- More than 3,000 square meters of advanced lab and production suites
- LDNA: 1 ug deliverable
- pDNA: micrograms to milligrams
- RNA synthesis: 100 ug to 10 g
- LNP microfluidics: 0.5–20 mg
- LNP traditional T mix: 0.1–1 mg
- LNP TurbMix by NAX: 1 mg–1 g
- High-throughput LDNA: minimum 10 sequences/order
- Therapeutic areas
- RNA therapeutics
- Gene editing
- In vivo cell therapy
- Animal immunization
- Immunization
Instruments and platforms
- Agilent 1260
- Agilent 1290 Infinity II Bio Inert
- Agilent LCMS QTOF
- Agilent FA 5300
- Sciex CE SDS
- Shimadzu FTIR spectrometer
- Real Time PCR
- Flow Cytometer
- Thermo Vanquish UPLC
- Plate washer
- Varioskan Plate Reader
- Chirascan v100
- TA Nano Differential Scanning Calorimeter (DSC)
- Beckman sedimentation velocity analytical ultracentrifugation
- Dynamic Light Scattering
Modalities and species
- Modalities
- Oligonucleotide
- mRNA
- Viral vector
- Cell therapy
- Gene editing
- Plasmid DNA
- LNP / formulation
- Species and models
- In vitro cell studies
- In vivo animal studies
- Gene editing
- In vivo cell therapy
- Animal immunization
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: early-phase manufacturing
Details
- Type
- CRDMO
- Founded
- 2025
- Address
- 2005 Eastpark Blvd Cranbury, New Jersey 08512, USA
- Sites
- United States, USA
- Serves
- United States, Europe, China